Wave Life Sciences

News

Wave's stock wavers on obesity drug data

Wave Life Sciences has said new clinical trial results with its non-incretin therapy for weight loss are positive – but investors don't seem to agree.

News

GSK departs Wave's AATD programme

Wave Life Sciences has lost GSK as the partner for its alpha-1 antitrypsin deficiency drug, but other partnered RNA-editing programmes remain active.

News

Measuring tape overlain on a dark yellow background

Pfizer's $2bn+ obesity bet, and other weight-loss news

Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

News

Wave Life Sciences president and CEO Paul Bolno

Wave surges on first RNA editing data in humans

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD).

News

Surfing on new Duchenne data, Wave charges $175m offering

Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to its highest level in a year and could lead to discussions with re

Wave's stock wavers on obesity drug data

GSK departs Wave's AATD programme

Pfizer's $2bn+ obesity bet, and other weight-loss news

Wave surges on first RNA editing data in humans

Surfing on new Duchenne data, Wave charges $175m offering

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

Wave Life Sciences

Editor's Picks